retatrutide update october 2025 (Eli Lilly's triple GLP-1/GIP/Glucagon receptor agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Can You Keep Weight Off

Insurance coverage will be a significant factor in accessibility

Frequently Asked Questions (AEO): What skin type is CELL:29 Riverfill Repair Cream best for

Then, we summarize clinical data from postmarketting surveillance, randomized controlled trials, and observational studies

Recent clinical guidelines increasingly recommend GLP-1RAs for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or are at high cardiovascular risk, regardless of baseline hemoglobin A1c levels

Starting with a modest dose to gauge bodily responses is prudent

oral administration (less studied for musculoskeletal use) Typical dosing range: 200-500 mcg once or twice daily